Christoph Nowak
Chief Tech/Sci/R&D Officer chez DIAMYD MEDICAL AB
Fortune : 585 $ au 31/03/2024
Profil
Christoph Nowak is currently an Independent Director at OncoZenge AB, a Chief Medical & Business Officer at Diamyd Medical AB, and a Chief Medical Officer at Melius Pharma AB.
Previously, he worked as an Assistant Professor at Karolinska Institutet.
He holds a doctorate degree from the University of Oxford, the University of Uppsala, and Technische Universität Braunschweig.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/08/2023 | 597 ( 0,00% ) | 585 $ | 31/03/2024 |
Postes actifs de Christoph Nowak
| Sociétés | Poste | Début |
|---|---|---|
| DIAMYD MEDICAL AB | Chief Tech/Sci/R&D Officer | - |
| ONCOZENGE AB | Director/Board Member | 09/09/2023 |
Melius Pharma AB
 Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Christoph Nowak
| Sociétés | Poste | Fin |
|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | - |
Formation de Christoph Nowak
| University of Oxford | Doctorate Degree |
| University of Uppsala | Doctorate Degree |
| Technische Universität Braunschweig | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DIAMYD MEDICAL AB | Health Technology |
| ONCOZENGE AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Health Technology |
